Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations.

HIV dolutegravir lamivudine molecular epidemiology rilpivirine

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 19 11 2019
accepted: 16 12 2019
entrez: 10 1 2020
pubmed: 10 1 2020
medline: 10 1 2020
Statut: epublish

Résumé

The frequency of clinically relevant transmitted drug resistance mutations (DRMs) against drugs used for 2-drug regimens was 15.6%, but only 2% were not eligible for 1 or more 2-drug regimens. More than 50% of patients harboring any clinically relevant DRMs were found to be part of genetic transmission clusters.

Identifiants

pubmed: 31915716
doi: 10.1093/ofid/ofz535
pii: ofz535
pmc: PMC6942491
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofz535

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI131971
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Clin Infect Dis. 2018 May 17;66(11):1794-1797
pubmed: 29293895
BMC Infect Dis. 2014 May 05;14:237
pubmed: 24885612
HIV Med. 2017 Oct;18(9):704-708
pubmed: 28444816
Lancet. 2019 Jan 12;393(10167):143-155
pubmed: 30420123
J Infect Dis. 2019 May 28;:null
pubmed: 31136663
Intervirology. 2012;55(2):98-101
pubmed: 22286876
Clin Infect Dis. 2019 Apr 24;68(9):1539-1546
pubmed: 30169606
Lancet. 2018 Mar 3;391(10123):839-849
pubmed: 29310899
Open Forum Infect Dis. 2018 Sep 08;5(10):ofy221
pubmed: 30568974
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
J Antimicrob Chemother. 2014 Jan;69(1):12-20
pubmed: 23934770
J Infect Dis. 2011 Oct 15;204(8):1191-201
pubmed: 21917892
Open Forum Infect Dis. 2018 Jul 20;5(8):ofy178
pubmed: 30151407

Auteurs

Harald H Kessler (HH)

Research Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.

Evelyn Stelzl (E)

Research Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.

Anja Blažič (A)

Research Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.

Sanjay R Mehta (SR)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.
Department of Medicine, San Diego VA Medical Center, San Diego, California, USA.

Anna S Benezeder (AS)

Research Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.

Christina Genger-Hackl (C)

Department of Gastroenterology and Infectious Diseases, Academic Hospital Graz II, Graz, Austria.

Brigitte I Santner (BI)

Research Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.

Antoine Chaillon (A)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.

Martin Hoenigl (M)

Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.
Division of Pulmonology and Section of Infectious Diseases, Medical University of Graz, Graz, Austria.

Classifications MeSH